Inventor
GABITZSCH ELIZABETH
US13 patents
⚠️ This page may combine multiple inventors who share the name “GABITZSCH ELIZABETH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ETUBICS CORP
9 patentsUS10695417B2Jun 30, 2020
Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
ETUBICS CORP9 citations83
US10563224B2Feb 18, 2020
Replication defective adenovirus vector in vaccination
ETUBICS CORP5 citations83
US11104916B2Aug 31, 2021
Compositions and methods for alphavirus vaccination
ETUBICS CORP6 citations82
US11149087B2Oct 19, 2021
Methods and compositions for combination immunotherapy
ETUBICS CORP2 citations71
US10835596B2Nov 17, 2020
Compositions and methods for flavivirus vaccination
ETUBICS CORP2 citations71
US11352642B2Jun 7, 2022
Methods and compositions for combination immunotherapy
ETUBICS CORP1 citations61
US11304998B2Apr 19, 2022
Combination immunotherapies comprising IL-15 superagonists
ETUBICS CORP1 citations60
US11116827B2Sep 14, 2021
Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
ETUBICS CORP1 citations60
US11020467B2Jun 1, 2021
Combination immunotherapies comprising IL-15 superagonists
ETUBICS CORP1 citations60
IMMUNITYBIO INC
3 patentsUS12274748B2Apr 15, 2025
Adenoviral vector transduced apheresis product
IMMUNITYBIO INC0 citations61
US12290558B2May 6, 2025
SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens
IMMUNITYBIO INC0 citations58
US11857620B2Jan 2, 2024
Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
IMMUNITYBIO INC0 citations58